Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — FY2021 Earnings Presentation
17 slides from Zealand Pharma A/s's earnings presentation, Mar 10, 2022
Slide 1: Full Year 2021 Report
Full Year 2021 Report Zealand Pharma 10 March 2022
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commerciali
Slide 3: Zealand Pharma in 2021
Zealand Pharma in 2021 Historical year as the company becomes a fully integrated biopharmaceutical company Launch of Zegalogue® with an optimized commercial team Execute on our robust late-stage clinical pipeline Advance our early-stage programs into the clinic Maintain a strong financial and organi
Slide 4: Our mission is to change lives with next generation peptide therapeutics
Our mission is to change lives with next generation peptide therapeutics 2025 ambition 5 commercialized products A continuously growing pipeline Advance potential Create a paradigm shift Key player in fast- Lead in SBS and CHI treatments options in Type 1 diabetes developing obesity rare diseases fo
Slide 5: ZEGALOGUE demand and utilization in Q4 2021
ZEGALOGUE® demand and utilization in Q4 2021 ~2000 ~500 unique prescription claims* prescribers*ᵼ ~2.0 average units ~60% repeat dispensed per Rx* prescribers* Sources: *Symphony weekly data, ᵼ Symphony True Benefit Design, ᵼ Zealand HUB Internal Prescription and Copay Utilization, through 12/31/202
Slide 6: ZEGALOGUE market access coverage continues to expand
ZEGALOGUE® market access coverage continues to expand % Covered Lives* – Commercial and Medicaid 95 70 50 50 16 10 Q3 2021 Q4 2021 Q1 2022 Commercial Medicaid Data Source: *Breakaway Partners FY 2021 presentation • 10 March 2022 6
Slide 7: Our Pipeline – therapeutic areas with high unmet medical needs
About Zealand Pharma Our Pipeline – 4 therapeutic areas with high unmet medical needs Product Candidate* Preclinical Phase 1 Phase 2 Phase 3 Registration diabetes Dasiglucagon Bi-Hormonal Artificial Pancreas Pump Type 1 Type 1 Diabetes management Dasiglucagon Low-Dose Pen T1D exercise-induced hypo ,
Slide 8: Gearing up for pivotal Phase 3 trial results for dasiglucagon in CHI
Rare Diseases Gearing up for pivotal Phase 3 trial results for dasiglucagon in CHI Trial 17109 Trial 17103 Trial 17106 32 patients 12 patients Up to 44 patients (>1 (3 months-12 years old) (7 days-12 months old) month old) Hypo-prone, maximum Patients from 17109 and Newly diagnosed, therapy, incl.P
Slide 9: Glepaglutide is being developed as a next generation GLP-2 in SBS
Rare Diseases Glepaglutide is being developed as a next generation GLP-2 in SBS Glepaglutide1 Phase 2 data showed increases in intestinal a long-acting stable GLP-2 analog absorption following 3-week administration • Forms depot at injection site with Change in wet weight Clear dose-response effecti
Slide 10: Preparing for glepaglutide Phase 3 Pivotal Trial results in Q3 2022
Preparing for glepaglutide Phase 3 Pivotal Trial results in Q3 2022 The Phase 3 program will provide up to 4.5 years patient exposure to glepaglutide and clinical evidence for efficacy and safety 10 FY 2021 presentation • 10 March 2022
Slide 11: BI 456906 is being investigated in three separate Phase 2 trials
Obesity BI 456906* is being investigated in three separate Phase 2 trials targeting diabetes, obesity and NASH Phase 1 Study of Glucagon-like Peptide-1/Glucagon ~1000 patients planned for enrollment Receptor Dual Agonist BI 456906 in Obesity** in the Phase 2 program Phase 1a: SAD trial Completed Hea
Slide 12: Amylin analogs hold potential as mono- and combination therapy for obesity
Obesity Amylin analogs hold potential as mono- and combination therapy for obesity Potent Effects of Amylin Analogue ZP8396 in ZP8396 in development for Combination with semaglutide in DIO Rats1 treatment of obesity • Long-acting, acylated amylin analog2 • Designed to allow for co- formulation with
Slide 13: Income statement
Income statement DKK million FY 2021 FY 2020 Revenue DKK 292.6 DKK 353.3 Gross margin 173.8 262.7 Research and Development expenses -588.5 -604.1 Sales and Marketing Expenses -375.3 -285.3 Administrative Expenses -261.0 -202.8 Net Operating Expenses -1,224.7 -1,092.1 Net Operating Result -1,052.4 -7
Slide 14: Balance sheet allows for continued investments
Balance sheet allows for continued investments Net Operating Expenses as of Dec. 31, 2021 Cash position as of Dec. 31, 2021 DKK 1,224.7 million / USD $186.7 million DKK 1.4 billion / USD $217.7 million DKK thousand DKK thousand 1,400,000 1,600,000 1,400,000 1,200,000 1,200,000 1,000,000 1,000,000 80
Slide 15: 2022 financial guidance
2022 financial guidance For 2022, net product revenue from the sales of commercial products is expected to be DKK 235 million +/- 10%. In 2022, Zealand Pharma expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand Pharma does n
Slide 16: Our 2025 ambition is to have 5 products on the market
Additional Company Information Our 2025 ambition is to have 5 products on the market and a highly valued pipeline leveraging our innovative peptide platform 2 in ’22 5 in ’25 Glepaglutide for SBS Proprietary peptide platform Our vision in Obesity Our vision in Dasiglucagon for CHI Inflammatory disea
Slide 17: Q&A session
Q&A session• FY 2021 presentation • 10 March 2022 17